AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01865916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol (PEG) + ascorbic acid
Description: Subjects will be asked to take split dose of 2L PEG and vitamin C
Study NCT01960530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone granules
Description: Multi-particulate granules
Study NCT01960530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Tablet
Description: Standard hydrocortisone tablets
Study NCT01960530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: i.v. Hydrocortisone Injection
Description: Standard hydrocortisone solution for intravenous injection
Study NCT01960530 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dexamethasone
Description: Challenge agent
Study NCT01301274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypotonic
Description: 0.45% NaCl/5% dextrose IV maintenance fluids
Study NCT01301274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotonic
Description: 0.9% NaCl/5% dextrose IV maintenance fluids
Study NCT05601934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurophysiological Facilitation Techniques
Description: Increased enlargement of the ribs during inspiration and increased movement in the epigastric region and tone of the abdominal muscles also decreased respiratory rate are some of the changes that occur after these stimuli. In addition to these, involuntary increase in cough, sputum production also decrease in pathological sounds felt on auscultation, decrease in aspiration requirement, rapid return in chest wall stabilization and improvement in respiratory pattern can be observed after application with this application, positive and long-term effective results can be seen in a short time.
Study NCT03322098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine injection (0.01 mg/kg, max 0.5 mg) within 3 minutes before spinal anesthesia
Study NCT03322098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) within 3 minutes before spinal anesthesia
Study NCT01468441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Triptorelin (0.1 mg, Gonapeptyl® Daily; Ferring, Kiel, Germany) in alternate-days from Day 1 of the menstrual cycle until the day of hCG administration.
Study NCT01468441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix
Description: When patients presented at least two follicles ≥ 14mm upon scan on days 7- 9, GnRH antagonist (cetrorelix, 0.25 mg/day, Cetrotide®; EMD Serono, Inc, Rockland, MA, USA) administration is started and continued until hCG administration.
Study NCT03269240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acquisition of Knowledge and clinical skills
Description: LDHF is a novel training approach that is being compared to the traditional training approach
Study NCT03269240 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acquisition of Knowledge and clinical skills
Description: LDHF is a novel training approach that is being compared to the traditional training approach
Study NCT03269240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Onsite training
Description: Participants are training at their health facilities
Study NCT03269240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Off-site training
Description: Participants from different health facilities are gathered together in a central location for training, away from their workplaces
Study NCT03684122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of Umbilical cord derived MSCs
Description: Allogenic umbilical cord derived MSCs which are to be injected intrathecally and intravenously as a treatment option for consenting PD patients
Study NCT03612492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Esmolol group (EG) will receive a bolus of esmolol 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min.
Study NCT03612492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine (LG) group will received lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.
Study NCT03207139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 PSMA ligand
Description: For PET/CT PSMA ligand scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA ligand . Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA ligand and received PET/CT scan 60 minutes later. The data acquisition begin with non-contrast CT at 120kVp, automated mAs, and a pitch of 1.5, followed by PET acquisition from the mid-thigh to skull-base, 3 minutes each bed. After image acquisition, the subject will be observed for half an hour, and will be discharged if no adverse event happens.~The estimated organ doses show that the kidneys and the urinary bladder wall were the organs with the highest dose. As presented, the effective doses for patients were 0.023 mSv/MBq ± 15% (maximum deviation), leading to an effective dose of 3.4 mSv for an injected activity of 150 MBq.
Study NCT03945864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: antimicrobial synthetic bone graft
Description: It will be determined whether the silver ion-doped antimicrobial synthetic bone graft that has the capacity to fill the bone voids also has the capacity to treat the infection in the bone in 12 patients with chronic osteomyelitis
Study NCT03945864 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: parentaral antimicrobials and pure bone grafts
Description: Historical data of the department will be used for comparison of the results
Study NCT01920399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ-AVI
Description: A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
Study NCT01920399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
Study NCT01309399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: six weeks of teriparatide
Study NCT01309399 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01680393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sequential compression device
Description: a sequential compression device will be applied to the legs
Study NCT01680393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TED stockings
Description: TED stockings will be applied to the patients legs during surgery
Study NCT03076944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UltraEZ
Description: Prophylaxis, apply uniformly on the teeth, wait 15 minutes, remove the gel from the teeth with cotton and abundant water.
Study NCT03076944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enamelast
Description: Prophylaxis; dry the teeth; apply uniformly on the teeth with a thin layer.
Study NCT04209855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.
Study NCT04209855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered per dose and schedule specified in the arm.
Study NCT04209855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan will be administered per dose and schedule specified in the arm.
Study NCT02944526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Monohydrochloride
Description: Suprascapular nerve block under ultrasound control: injection of 5ml Ropivacaine HCL 2mg /ml
Study NCT04209855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
Study NCT02210793 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transepithelial PRK
Study NCT02210793 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK
Study NCT02329184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-461
Study NCT02730182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: altitude exposure
Description: altitude exposure
Study NCT01057784 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery.
Description: Bariatric Surgery
Study NCT03062202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SilverCloud
Description: SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
Study NCT02516722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Intra-Vascular UltraSound (TIVUS™) System
Description: The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.~Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation.
Study NCT02975635 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Patients are given a questionnaire with items related to personality and behaviour.
Study NCT02944526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: Placebo suprascapular nerve block under ultrasound control: injection of 5ml physiological / isotonic saline
Study NCT04433962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Study NCT04433962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Study NCT00830622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cell Phone Intervention
Description: Participant receives weekly SMS text messages from the health care provider.
Study NCT01580839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue Plasminogen Activator (Alteplase)
Description: 0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
Study NCT01580839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
Study NCT05613114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalfampridine 10 MG
Description: The participants in the experimental group received dalfampridine administered as 10 mg extended-release tablets every twelve hours for 8 weeks.
Study NCT05613114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group received a placebo drug with the same administration method (2 times per week for the total duration of 8 weeks).
Study NCT05613114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Conventional physiotherapy program including stretching and flexibility, strengthening, walking and balance exercises which were mainly focused on the lower limbs and improving walking. The program was applied 2 times per week for the total duration of 8 weeks.
Study NCT05613114 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy
Description: Conventional physiotherapy program including stretching and flexibility, strengthening, walking and balance exercises which were mainly focused on the lower limbs and improving walking. The program was applied 2 times per week for the total duration of 8 weeks.
Study NCT04665024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoperative chest physiotherapy
Description: The patients were approached to partake in the investigation after they got full clarifications about the point of study. They were allocated into two groups and reassurance was achieved about the absence of any side effects.Furthermore, the examination was approved by the ethical committee.~Effects of preoperative chest physiotherapy were compared between two groups, by measuring the lung functions, oxygen saturation, pulmonary complications and length of hospital staying. Lung functions were completed by utilizing spirometry parameters, oxygen saturation was measured by pulse oximeter and pulmonary complications were diagnosed by specialist doctors.
Study NCT04665024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postoperative chest physiotherapy
Description: Postoperative chest physiotherapy made in both two groups was similar to the preoperative chest physiotherapy but this was achieved by physiotherapists and made once a day for 10-25 minutes depending on the lectures of postoperative days.
Study NCT00855010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: pioglitazone 45 mg daily
Study NCT04713878 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stem cells
Description: Intravenous infusion of Mesenchymal stem cells
Study NCT02162771 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan
Study NCT02162771 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P10
Study NCT00855010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one daily
Study NCT05956704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology with aspheric wide inversion zone design in the optical zone
Description: An orthokeratology lens with an altered optical zone design is designed for an aspherical wide inversion arc in the optical zone
Study NCT05956704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthokeratology with traditional spherical design in the optical zone
Description: Subjects wore the orthokeratology with traditional spherical design in the optical zone
Study NCT02630095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin Calcium and Warfarin
Description: Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3, and during the of perioperative period of Endoscopic treatment changing to use Nadroparin Calcium 4100IU／d，subcutaneous.
Study NCT02630095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound and CT
Description: all patient will take Doppler ultrasound examination every 3 months ；Abdominal CT will be done every 6 months。
Study NCT02630095 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Doppler ultrasound and CT
Description: all patient will take Doppler ultrasound examination every 3 months ；Abdominal CT will be done every 6 months。
Study NCT03800732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: With Meal during night work
Description: Two nights of work with a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
Study NCT03800732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Without Meal during night work
Description: Two nights of work without a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
Study NCT03800732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep night
Description: Two sleep nights and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
Study NCT02166736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFR
Description: Treatment guided by Instantaneous wave-free ratio (iFR®)
Study NCT00045435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo nonmyeloablative allogeneic PBSC transplant
Study NCT00045435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00045435 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study NCT00045435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO
Study NCT00045435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO
Study NCT00045435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo nonmyeloablative allogeneic PBSC transplant
Study NCT03390777 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: surgery without the use of prgf
Study NCT03390777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRGF after surgery
Description: surgery and application of PRGF
Study NCT02826967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonic Irrigation
Study NCT00738101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 5 years. If the infant no longer is requiring any TPN, then the Omegaven will be stopped regardless of bilirubin. If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
Study NCT03573661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast Cancer Locator (BCL)
Description: This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
Study NCT03430141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritarian Diet-style
Description: Nutritarian Diet-style: Daily consumption of greens, beans/legumes, a variety of other vegetables, fresh or frozen fruits, nuts, seeds and whole grains. Participants are encouraged to minimize consumption of refined grains, vegetable oils, processed foods, and to limit animal products.
Study NCT01424475 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Healthy
Description: Healthy Volunteers
Study NCT01424475 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: PKD Patients
Description: PKS Patients
Study NCT01542060 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Administered via an insulin injection device. Dosages varied according to individual patients' medical requirement as determined by their attending clinician
Study NCT01204268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sev-I group
Description: Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.
Study NCT01204268 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sevo continuous inhalation
Description: Patients will receive the anesthesia with continuous inhalation of sevoflurane.
Study NCT02166736 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FFR
Description: Intervention guided by Fractional Flow Reserve
Study NCT04576364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate for 12 hour
Description: drug used to prevent convulsions in patients having preeclampsia with severe features